All In Biotech

Drug Trial Radar · NCT04383925

Trial to Compare Two Strains of BCG

Randomized Trial Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Effects on Early-life Mortality and Morbidity

Last checked: Nov 19, 2026Latest source record: Jan 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 16,390 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16,390

Actual

Start

May 4, 2020

Primary completion

Oct 30, 2022

Study completion Dec 1, 2022

Sponsor

Lead sponsor
Bandim Health ProjectAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Southern Denmark
First posted
May 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 0 days, up to 42 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to mortality, morbidity and case-fatality rate during hospital admission. The trial will also examine the association between BCG strains and BCG skin reaction characteristics by six weeks (data collected by telephone) and at two and six months (data collected at home-visits to a subgroup of the cohort). As a secondary aim, this large study will be used to further evaluate the role of maternal BCG immune priming for overall health, since there are indications that maternal BCG scarring enhances the non-specific effects of BCG.

Conditions

  • Death, Infant
  • Morbidity;Infant

Interventions

  • BCG-JapanBiological

    Infant (\<1 year) 0.05 ml dose of resuspended BCG-Japan (Tokyo strain 172, Japan BCG Laboratory, 1-5-21 Otsuka, Bunkyo-ku, Tokyo, 112-0012 Japan).

  • BCG-RussiaBiological

    Infant (\<1 year) 0.05 ml dose of resuspended BCG-Russia (Serum Institute of India)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of all-cause mortality overall and stratified by maternal BCG scar status and sexTime frame: Six weeks of age

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bandim Health Project

    Bissau, Guinea-Bissau

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.